Steve Brozak
Stock Analyst at WBB Securities
(1.19)
# 3,772
Out of 4,964 analysts
9
Total ratings
44.44%
Success rate
-4.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELU Celularity | Initiates: Speculative Buy | $6 | $3.85 | +55.84% | 1 | Aug 18, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Strong Buy | $45 | $65.23 | -31.01% | 2 | Jun 23, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $0.90 | +1,294.93% | 1 | Apr 1, 2025 | |
| OMER Omeros | Maintains: Strong Buy | $75 → $100 | $4.23 | +2,264.07% | 2 | Jun 18, 2021 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.32 | +1,212,021.21% | 3 | May 28, 2021 |
Celularity
Aug 18, 2025
Initiates: Speculative Buy
Price Target: $6
Current: $3.85
Upside: +55.84%
Cidara Therapeutics
Jun 23, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $65.23
Upside: -31.01%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $0.90
Upside: +1,294.93%
Omeros
Jun 18, 2021
Maintains: Strong Buy
Price Target: $75 → $100
Current: $4.23
Upside: +2,264.07%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.32
Upside: +1,212,021.21%